Peptides and the Hallmarks of Aging: Evidence Map

Compare FOXO4-DRI, Epitalon, Humanin, GHK-Cu, and BPC-157 by aging hallmark, evidence level, human data, safety, and regulatory status.

The hallmarks of aging are a research framework for organizing biological changes associated with aging. They are not a checklist that turns every molecule affecting one pathway into an “anti-aging therapy.”

FOXO4-DRI, Epitalon, Humanin, GHK-Cu, and BPC-157 are frequently mapped to hallmarks in peptide marketing. That mapping can generate a testable hypothesis. It does not establish longer life, better healthspan, disease prevention, or a safe human protocol.

Short answer

The 2023 update to the hallmarks framework describes 12 interconnected hallmarks, not 13 independent treatment targets.
A cell, worm, or mouse result is not human anti-aging evidence, even when the measured pathway is a recognized hallmark.
FOXO4-DRI remains a preclinical senolytic candidate; the foundational intervention study was conducted in cells and mice.
Epitalon has cell-culture telomerase findings, but these do not demonstrate longer or healthier human life. Epitalon is also not interchangeable with Epithalamin, a pineal extract used in older reports.
Human studies measuring naturally occurring Humanin are observational. They do not show that administering Humanin or the more potent HNG analog improves human aging outcomes.
GHK-Cu has limited, route-specific human cosmetic evidence. Topical skin outcomes do not establish systemic rejuvenation or injectable safety.
A 2025 BPC-157 systematic review found 35 preclinical studies and one small human study; none tested aging or lifespan.
FDA currently identifies BPC-157, Epitalon, and injectable GHK-Cu among bulk substances that may present significant safety risks in compounding. This status is different from drug approval.

What the 12 hallmarks mean

The updated framework includes:

genomic instability;
telomere attrition;
epigenetic alterations;
loss of proteostasis;
disabled macroautophagy;
deregulated nutrient sensing;
mitochondrial dysfunction;
cellular senescence;
stem-cell exhaustion;
altered intercellular communication;
chronic inflammation; and
dysbiosis.

The authors proposed three criteria for a hallmark: it appears with age, experimentally making it worse accelerates aging, and experimentally acting on it can decelerate, stop, or reverse aspects of aging. Those are framework criteria derived across model systems. They are not proof that any particular commercial product changes aging in people.

The hallmarks are also connected. A compound can alter several laboratory markers without producing a net benefit, while a useful treatment may improve a disease outcome without “reversing” a hallmark.

Evidence map for five frequently marketed peptides

Compound	Proposed hallmark connection	Best relevant evidence	Human intervention evidence	Defensible conclusion
FOXO4-DRI	Cellular senescence and inflammatory signaling	Selective effects in senescent cells and improved selected outcomes in aged or injured mice	No established human intervention trial demonstrating safety or benefit	A preclinical senolytic research tool, not a demonstrated human rejuvenation treatment
Epitalon / Epithalon	Telomere attrition, epigenetic regulation, circadian signaling	Telomerase and telomere findings in cultured human cells; animal studies	Older human reports are sparse and often concern Epithalamin, a different pineal extract	Cell plausibility with unresolved identity, replication, clinical efficacy, and safety questions
Humanin / HNG	Mitochondrial dysfunction, stress signaling, autophagy	Cell, worm, and mouse studies; HNG altered selected metabolic and tissue outcomes in mice	Human studies mainly measure endogenous Humanin concentrations or genetic variants rather than administering the peptide	An endogenous mitochondrial-derived peptide with strong preclinical interest but no established anti-aging treatment evidence
GHK-Cu	Extracellular-matrix maintenance, inflammation, tissue repair	Large preclinical literature and a small number of route-specific cosmetic trials	A 2026 review found 18 preclinical studies and two randomized trials in aesthetic medicine	Limited formulation-specific topical evidence; no basis for a systemic longevity or injectable claim
BPC-157	Tissue stress, angiogenesis, inflammation, repair signaling	Mostly rodent injury and disease models	One small, uncontrolled musculoskeletal report within a 2025 review; no clinical aging study	Insufficient human efficacy and safety evidence, with no demonstrated effect on lifespan or healthspan

FOXO4-DRI and cellular senescence

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt an interaction between FOXO4 and p53. The 2017 foundational paper reported selective apoptosis in some senescent-cell models and improvements in fur density, activity, and renal measures in naturally aged or accelerated-aging mice.

That study supports a senolytic hypothesis. It does not show that all senescent cells should be removed, that FOXO4-DRI is selective across human tissues, or that a human dose would be safe. Senescence can help suppress tumors, coordinate wound repair, and limit damaged-cell proliferation. Effects can depend on cell type, trigger, tissue, and timing.

Statements such as “FOXO4-DRI reverses aging” compress a mouse experiment, selected outcomes, and an untested human translation into one unsupported claim.

Epitalon, Epithalamin, and telomeres

Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly. Epithalamin is a mixture extracted from animal pineal tissue. They should not be treated as synonyms, and a clinical report about one cannot validate the other.

A 2003 study exposed telomerase-negative human fetal fibroblasts to Epitalon and reported telomerase expression and telomere elongation. A 2025 study also reported telomere-related changes in treated human cell lines. “Human cells” in a laboratory dish is not the same evidence unit as administering a product to people.

Telomere length is not a standalone score for whole-body aging. It varies across cell types and measurement methods, and telomerase biology intersects with cancer. A finding that cells completed additional divisions cannot be translated into a percentage increase in human lifespan.

As of this review, FDA’s safety-risk page says compounded Epitalon may pose immunogenicity risks related to aggregation and peptide impurities, and that the agency lacks safety-related information for the proposed route. That is not a finding that every exposure is harmful; it is a clear limit on claims of established safety.

Humanin and mitochondrial signaling

Humanin is an endogenous mitochondrial-derived peptide. HNG is a synthetic analog with a serine-to-glycine substitution and greater activity in many assays. Results for HNG should not be silently relabeled as results for unmodified Humanin.

In one aging study, small groups of female mice received HNG from 18 to 32 months of age. Investigators reported less cardiac fibrosis and apoptosis at necropsy. Other work reported lifespan or health-related signals in worms and mice.

Human cohorts have associated circulating Humanin levels or variants with age, disease, or exceptional longevity. These studies can investigate Humanin as a marker or part of a pathway. They do not establish that externally administered Humanin improves healthspan. ClinicalTrials.gov records involving Humanin are largely observational biomarker studies rather than therapeutic trials.

GHK-Cu and tissue repair

GHK-Cu is a copper-binding tripeptide studied in extracellular-matrix biology, inflammation, wound models, and cosmetic formulations. Its best human evidence is narrower than broad “regeneration” language suggests.

A 2026 systematic review found 20 eligible aesthetic studies: 18 were preclinical and two were randomized trials. The human signal is therefore formulation- and route-specific. It does not show that injection changes systemic aging, nor can topical findings validate a research vial.

FDA separately identifies injectable GHK-Cu as presenting potential immunogenicity risks from aggregation and peptide-related impurities, with limited human safety information. See the route-specific GHK-Cu evidence guide for the detailed breakdown.

BPC-157 and repair signaling

BPC-157 is commonly connected to inflammation, angiogenesis, and tissue repair. Those mechanisms overlap with several hallmarks, but overlap is not clinical validation.

The 2025 systematic review of musculoskeletal research included 36 studies: 35 preclinical studies and one small human report involving 12 people with chronic knee pain. It found no clinical human safety dataset. Neither the human report nor the animal literature tested lifespan, multimorbidity, frailty, or a validated healthspan endpoint.

FDA says compounded BPC-157 may present immunogenicity and peptide-impurity risks and that it has no or limited safety information for proposed routes. The BPC-157 evidence guide separates animal findings, the limited human record, and current regulatory context.

What would count as human anti-aging evidence?

No single laboratory marker can prove that an intervention slows human aging. A persuasive program would need:

a precisely characterized product and route;
phased human safety and pharmacokinetic studies;
randomized, blinded, adequately powered trials;
prespecified outcomes meaningful to people, such as physical or cognitive function, disease incidence, disability, or survival;
validated biomarker panels used alongside—not instead of—clinical outcomes;
enough follow-up to detect delayed harms;
independent replication; and
transparent adverse-event, dropout, funding, and conflict reporting.

Changing telomerase activity, cytokine expression, collagen staining, mitochondrial markers, or senescence-associated proteins can support a mechanism. It cannot by itself support “reverses biological age.”

Regulatory and sourcing boundary

Research compounds, compounded drugs, cosmetics, supplements, and FDA-approved medicines are different categories.

Research-use material is not authorized for self-administration.
Compounded drugs are not FDA approved; FDA does not review their safety, effectiveness, or quality before marketing.
A substance discussed by an FDA compounding advisory committee has not thereby become approved or proven effective.
FDA’s safety-risk list currently discusses BPC-157, Epitalon, and injectable GHK-Cu. Absence of FOXO4-DRI or Humanin from that list would not establish safety, legality, or suitability.
Topical cosmetic evidence cannot be transferred to injection, and animal dose information is not a human protocol.

For laboratory sourcing, verify exact identity, sequence and modifications, salt or complex form, lot linkage, mass-spectrometry support, chromatographic method, storage, and route-relevant quality attributes. The purity-testing guide explains why a purity percentage is not identity, sterility, or clinical evidence.

Use the sourcing framework to evaluate seller documentation and the source availability and batch-record directory to compare disclosed records. The directory is an informational index, not a recommendation to purchase or use a product.

References

López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell. 2023;186:243–278.
Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169:132–147.e16.
Khavinson VK, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135:590–592.
Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025.
Qin Q, et al. Chronic treatment with the mitochondrial peptide Humanin prevents age-related myocardial fibrosis in mice. American Journal of Physiology—Heart and Circulatory Physiology. 2018;315:H1127–H1136.
Yen K, et al. The mitochondrial derived peptide Humanin is a regulator of lifespan and healthspan. Aging. 2020;12:11185–11199.
Mokhtar J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthetic Surgery Journal. 2026.
Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Orthopaedic Journal of Sports Medicine. 2025;21:485–495.
U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks.
U.S. Food and Drug Administration. Compounding and FDA: questions and answers.
ClinicalTrials.gov. Search for Humanin studies.

Bottom line

The hallmarks framework helps researchers ask where a peptide might act; it does not answer whether that peptide slows human aging. FOXO4-DRI and Humanin remain preclinical intervention stories, Epitalon’s telomere claims rely heavily on cell work and identity-confounded older literature, GHK-Cu has limited route-specific cosmetic evidence, and BPC-157 has almost no human efficacy or safety record. Any commercial pathway should preserve those differences and lead with exact identity, route, evidence level, and verifiable batch documentation.

Peptides and the Hallmarks of Aging: Evidence Map

On this page